Assignee
AURIGENE ONCOLOGY LTD
IN·15 granted patents·24 pending applications·5 citations·filing 2019–2025
Top patents by PatentIndex Score
39 records- 0194US11981685B2Bicyclic heterocyclyl derivatives as IRAK4 inhibitorsAURIGENE ONCOLOGY LTD·Filed 2023·Granted May 14, 2024·1 cites·5 claims
- 0290US12064418B2Conjoint therapies for immunomodulationAURIGENE ONCOLOGY LTD·Filed 2022·Granted Aug 20, 2024·2 cites·15 claims
- 0390US12005045B2Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compoundsAURIGENE ONCOLOGY LTD·Filed 2023·Granted Jun 11, 2024·1 cites·19 claims
- 0489US12410193B2Bicyclic heterocyclyl derivatives as IRAK4 inhibitorsAURIGENE ONCOLOGY LTD·Filed 2024·Granted Sep 9, 2025·0 cites·9 claims
- 0589US2025361244A1Bicyclic heterocyclyl derivatives as irak4 inhibitorsAURIGENE ONCOLOGY LTD·Filed 2025·Application pending·0 cites
- 0689US2026022102A11,2,4-Oxadiazole and Thiadiazole Compounds as ImmunomodulatorsAURIGENE ONCOLOGY LTD·Filed 2025·Application pending·0 cites
- 0785US12187689B2Crystalline forms of 3-substituted 1,2,4-oxadiazoleAURIGENE ONCOLOGY LTD·Filed 2023·Granted Jan 7, 2025·0 cites·32 claims
- 0883US12226402B2Dual inhibitors of TIM-3 and PD-1 pathwaysAURIGENE ONCOLOGY LTD·Filed 2023·Granted Feb 18, 2025·0 cites·14 claims
- 0983US11560403B21,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathwaysAURIGENE ONCOLOGY LTD·Filed 2021·Granted Jan 24, 2023·1 cites·16 claims
- 1083US2025136562A1Crystalline forms of 3-substituted 1,2,4- oxadiazoleAURIGENE ONCOLOGY LTD·Filed 2024·Application pending·0 cites
- 1180US2025332155A1Substituted tetrahydroquinolinone compounds as ror gamma modulatorsAURIGENE ONCOLOGY LTD·Filed 2025·Application pending·0 cites
- 1277US12565515B21,2,4-oxadiazole compounds as inhibitors of CD47 signalling pathwaysAURIGENE ONCOLOGY LTD·Filed 2023·Granted Mar 3, 2026·0 cites·20 claims
- 1376US2024156814A1Method for Treating Diseases Using SMARCA2/4 DegradersAURIGENE ONCOLOGY LTD·Filed 2024·Application pending·0 cites
- 1474US12377088B2Substituted tetrahydroquinolinone compounds as ROR gamma modulatorsAURIGENE ONCOLOGY LTD·Filed 2022·Granted Aug 5, 2025·0 cites·15 claims
- 1574US2025195478A1Dual inhibitors of vista and pd-1 pathwaysAURIGENE ONCOLOGY LTD·Filed 2024·Application pending·0 cites
- 1671US12268670B2Combination of small molecule CD-47 inhibitors with other anti-cancer agentsAURIGENE ONCOLOGY LTD·Filed 2022·Granted Apr 8, 2025·0 cites·21 claims
- 1771US2024270734A1Pyridazine Derivatives as SMARCA2/4 DegradersAURIGENE ONCOLOGY LTD·Filed 2024·Application pending·0 cites
- 1870US12331023B2Substituted heterocyclyl derivatives as CDK inhibitorsAURIGENE ONCOLOGY LTD·Filed 2021·Granted Jun 17, 2025·0 cites·95 claims
- 1968US12290507B2Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitorsAURIGENE ONCOLOGY LTD·Filed 2021·Granted May 6, 2025·0 cites·4 claims
- 2067US2025144082A1Dual inhibitors of tim-3 and pd-1 pathwaysAURIGENE ONCOLOGY LTD·Filed 2025·Application pending·0 cites
- 2164US2025177358A1Combination of small molecule cd-47 inhibitors with other anti-cancer agentsAURIGENE ONCOLOGY LTD·Filed 2025·Application pending·0 cites
- 2263US2026097019A1Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitorsAURIGENE ONCOLOGY LTD·Filed 2025·Application pending·0 cites
- 2362US2026000692A1Substituted N-(Pyridin-2-yl)Acetamide Derivatives as CDK12/13 InhibitorsAURIGENE ONCOLOGY LTD·Filed 2023·Application pending·0 cites
- 2461US2024246917A1Process for preparing a cdk inhibitorAURIGENE ONCOLOGY LTD·Filed 2022·Application pending·0 cites
- 2558US11866420B2Hydrochloride salt forms of a sulfonamide structured kinase inhibitorAURIGENE ONCOLOGY LTD·Filed 2019·Granted Jan 9, 2024·0 cites·14 claims
- 2658US2025092066A1Substituted bicyclic heterocycles as malt-1 inhibitorsAURIGENE ONCOLOGY LTD·Filed 2023·Application pending·0 cites
- 2757US2025059204A1Fused benzoisoxazolyl compounds as kat6a inhibitorsAURIGENE ONCOLOGY LTD·Filed 2022·Application pending·0 cites
- 2856US11633394B2Substituted alkynylene compounds as anticancer agentsAURIGENE ONCOLOGY LTD·Filed 2019·Granted Apr 25, 2023·0 cites·30 claims
- 2956US2023210847A1Substituted Alkynylene Compounds As Anticancer AgentsAURIGENE ONCOLOGY LTD·Filed 2023·Application pending·0 cites
- 3055US2024132475A1Substituted pyrazolyl compounds as malt-1 inhibitorsAURIGENE ONCOLOGY LTD·Filed 2022·Application pending·0 cites
- 3155US2023414605A1Method of Treating Cancer Using FABP5 InhibitorsAURIGENE ONCOLOGY LTD·Filed 2021·Application pending·0 cites
- 3254US2025145609A13-substituted pyridazine compounds as smarca2 and/or smarca4 degradersAURIGENE ONCOLOGY LTD·Filed 2023·Application pending·0 cites
- 3352US2024059669A1Cocrystal of a cdk inhibitorAURIGENE ONCOLOGY LTD·Filed 2021·Application pending·0 cites
- 3451US2024254139A1Fused isoxazolyl compounds as kat6a inhibitorsAURIGENE ONCOLOGY LTD·Filed 2022·Application pending·0 cites
- 3551US2024277722A1Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agentAURIGENE ONCOLOGY LTD·Filed 2022·Application pending·0 cites
- 3650US2023322724A1Heterocyclic compounds as cbp/ep300 bromodomain inhibitorsAURIGENE ONCOLOGY LTD·Filed 2021·Application pending·0 cites
- 3748US2024016811A1Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agentAURIGENE ONCOLOGY LTD·Filed 2021·Application pending·0 cites
- 3845US12570650B26-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degradersAURIGENE ONCOLOGY LTD·Filed 2021·Granted Mar 10, 2026·0 cites·27 claims
- 3944US2025339404A1COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINEAURIGENE ONCOLOGY LTD·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when AURIGENE ONCOLOGY LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →